As Allergan (AGN) faces pressure from a big hedge fund for “chronic underperformance,” a survey of doctors suggests the drug maker may be “overly sanguine” about new competition for its Botox wrinkle smoother, and that sales growth and operating margins for the key product could take a hit.

Specifically, more than 75 percent of dermatologists reported they would be at least moderately more likely to offer a forthcoming treatment called Jeuveau to their existing Botox patients, if the new medication costs significantly less for them to purchase. Notably, Wall Street analysts expect Evolus (EOLS), which recently won regulatory approval for Jeuveau, to sell its drug at a discount of up to 25 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hello Stat Plus,
    My partner and I are interested in signing up for your service; but we have three very important questions first:
    1)Do you give us advance warning of an IPO, and the preliminary descriptions of what’s going on with the testing, and
    2)Do you give us advance notice when one company is planning on, or about to, buy another company (as with Roche buying Sparks Therapeutics? How much in advance will we know both in advance, and lastly,
    3)Regarding Pipelines, we are very interested in knowing the approval status of drugs in the Pipeline; will you be providing that info?
    Thank you very much. I look forward to your answers, and then we’re SIGNING UP!
    All the best, Laurie Lee (Individual Investor)

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy